Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Registry-based randomized double-blind placebo-controlled trial of dapagliflozin in acute myocardial infarction and heart failure
2020-000664-31Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) and heart failure (HF) comparing Dapagliflozin arm with Placebo arm (2 arms). Primary endpoint: Hierarchical composite primary endpoint. Started May 2020; status: completed.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)heart failure (HF)
Beyond the preview
Go deeper on 2020-000664-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000664-31.